A Phase I Two-Dimensional Dose-Finding Study of Ixazomib in Combination With Gemcitabine and Doxorubicin, Followed by a Phase II Extension to Assess the Efficacy of This Combination in Metastatic, Surgically Unresectable Urothelial Cancer

Trial Profile

A Phase I Two-Dimensional Dose-Finding Study of Ixazomib in Combination With Gemcitabine and Doxorubicin, Followed by a Phase II Extension to Assess the Efficacy of This Combination in Metastatic, Surgically Unresectable Urothelial Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Nov 2016

At a glance

  • Drugs Ixazomib (Primary) ; Doxorubicin; Gemcitabine
  • Indications Bladder cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Jul 2015 Planned primary completion date changed from 1 Jun 2021 to 1 Jul 2021, according to ClinicalTrials.gov record.
    • 06 Jul 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
    • 23 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top